UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 62

of 'The role of local therapies in metastatic breast cancer'

62
TI
Metastatic breast carcinoma to the abdomen and pelvis.
AU
Abu-Rustum NR, Aghajanian CA, Venkatraman ES, Feroz F, Barakat RR
SO
Gynecol Oncol. 1997;66(1):41.
 
OBJECTIVE: The role of surgical resection of metastatic breast cancer to the abdomen and pelvis is controversial. The objective of this study is to describe the characteristics, surgical management, and outcome of women with a history of breast adenocarcinoma who developed abdominal or pelvic metastases during follow-up.
METHODS: We retrospectively reviewed the medical records of 40 female patients with documented invasive breast cancer who were referred to the Gynecology Service between 1986 and 1995 and were found to have metachronous abdominal and/or pelvic metastases.
RESULTS: The median patient age at exploration by the Gynecology Service was 53.5 years (range 27-79 years), and the median interval from breast cancer diagnosis to exploration was 80 months (range 9-264 months). The majority of patients, 32 (80%), had a preoperative diagnosis of a new pelvic mass or suspected abdominal carcinomatosis. With a median follow-up of 14.2 months following the diagnosis of abdominal or pelvic metastasis, the median survival for all patients was 24.1 months. Patients who had no gross residual disease in the abdomen or pelvis after surgery had a median survival of41.6 months, which did not significantly differ from those with gross residual<or =2 cm (16.1 months) or>2 cm (18.4 months) (P = 0.624).
CONCLUSION: Metachronous abdominal and pelvic metastases from breast cancer may appear many years following initial diagnosis and are often operated on by gynecologists because of their clinical presentation. Surgical resection may be indicated in some symptomatic patients; however, the survival advantage of surgical cytoreduction remains to be determined.
AD
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
PMID